Otis Littlefield is an associate in the San Francisco office. His practice focuses on representing life science clients, including biotechnology, pharmaceutical, agricultural biotechnology, and medical device companies.

He specializes in two main areas: intellectual property-related business transactions and patent prosecution, including patent portfolio strategy, management, and evaluation. He has expertise in vaccines and adjuvants, stem cell therapeutics, molecular biology, diagnostics, high throughput screening and microarray technologies, gene therapy, bioinformatics, medical devices, and plant molecular biology and breeding. His practice includes drafting and prosecuting patent applications, including interferences and re-examinations. Dr. Littlefield’s practice also includes conducting due diligence studies in connection with venture capital, private and public financing, and mergers and acquisitions.

In the intellectual property-related business transactions, he has represented a variety of life science companies on a broad range of transactions, including in- and out-licenses, drug discovery and development agreements, clinical trial agreements, manufacture and supply agreements, joint research and development agreements, commercialization agreements, strategic joint ventures, and mergers and acquisitions.

Dr. Littlefield received a B.S. in chemistry and biology from Purdue University and a Ph.D. in molecular and cellular biology from the University of California at Berkeley. His doctoral thesis work focused on structural studies of the eukaryotic heat shock transcription factor binding to DNA. He worked as a post-doctoral research associate at Yale University, where he conducted structural studies of basal transcription initiation of RNA polymerase. Dr. Littlefield received a J.D. from the University of California at Berkeley. He is a member of the State Bar of California and is registered to practice before the United States Patent and Trademark Office.